nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK8—skin epidermis—vulva cancer	0.0535	0.0535	CbGeAlD
Nilotinib—KIT—skin epidermis—vulva cancer	0.0223	0.0223	CbGeAlD
Nilotinib—CDC42BPB—uterine cervix—vulva cancer	0.0191	0.0191	CbGeAlD
Nilotinib—CDC42BPB—urethra—vulva cancer	0.0176	0.0176	CbGeAlD
Nilotinib—MAPK8—epithelium—vulva cancer	0.0174	0.0174	CbGeAlD
Nilotinib—MAPK8—uterine cervix—vulva cancer	0.0173	0.0173	CbGeAlD
Nilotinib—MAPK8—urethra—vulva cancer	0.0159	0.0159	CbGeAlD
Nilotinib—TIE1—epithelium—vulva cancer	0.0151	0.0151	CbGeAlD
Nilotinib—TIE1—uterine cervix—vulva cancer	0.015	0.015	CbGeAlD
Nilotinib—EPHB3—uterine cervix—vulva cancer	0.0143	0.0143	CbGeAlD
Nilotinib—TIE1—urethra—vulva cancer	0.0138	0.0138	CbGeAlD
Nilotinib—MAP4K1—mammalian vulva—vulva cancer	0.0137	0.0137	CbGeAlD
Nilotinib—EPHB3—urethra—vulva cancer	0.0131	0.0131	CbGeAlD
Nilotinib—HCK—uterine cervix—vulva cancer	0.0131	0.0131	CbGeAlD
Nilotinib—CDC42BPB—vagina—vulva cancer	0.0129	0.0129	CbGeAlD
Nilotinib—EPHB3—mammalian vulva—vulva cancer	0.0125	0.0125	CbGeAlD
Nilotinib—HCK—urethra—vulva cancer	0.012	0.012	CbGeAlD
Nilotinib—CA3—uterine cervix—vulva cancer	0.0118	0.0118	CbGeAlD
Nilotinib—MAPK8—vagina—vulva cancer	0.0117	0.0117	CbGeAlD
Nilotinib—HCK—mammalian vulva—vulva cancer	0.0115	0.0115	CbGeAlD
Nilotinib—MAPK14—epithelium—vulva cancer	0.0111	0.0111	CbGeAlD
Nilotinib—MAPK14—uterine cervix—vulva cancer	0.011	0.011	CbGeAlD
Nilotinib—EPHA4—urethra—vulva cancer	0.0109	0.0109	CbGeAlD
Nilotinib—LCK—uterine cervix—vulva cancer	0.0109	0.0109	CbGeAlD
Nilotinib—MAP4K1—vagina—vulva cancer	0.0106	0.0106	CbGeAlD
Nilotinib—EPHB4—epithelium—vulva cancer	0.0105	0.0105	CbGeAlD
Nilotinib—EPHA4—mammalian vulva—vulva cancer	0.0104	0.0104	CbGeAlD
Nilotinib—EPHB4—uterine cervix—vulva cancer	0.0104	0.0104	CbGeAlD
Nilotinib—EPHA2—epithelium—vulva cancer	0.0103	0.0103	CbGeAlD
Nilotinib—EPHA2—uterine cervix—vulva cancer	0.0102	0.0102	CbGeAlD
Nilotinib—LCK—urethra—vulva cancer	0.01	0.01	CbGeAlD
Nilotinib—FGR—urethra—vulva cancer	0.01	0.01	CbGeAlD
Nilotinib—TEK—epithelium—vulva cancer	0.01	0.01	CbGeAlD
Nilotinib—BRAF—vagina—vulva cancer	0.00973	0.00973	CbGeAlD
Nilotinib—EPHB3—vagina—vulva cancer	0.00966	0.00966	CbGeAlD
Nilotinib—BLK—lymph node—vulva cancer	0.00958	0.00958	CbGeAlD
Nilotinib—FGR—mammalian vulva—vulva cancer	0.00956	0.00956	CbGeAlD
Nilotinib—LCK—mammalian vulva—vulva cancer	0.00956	0.00956	CbGeAlD
Nilotinib—EPHB4—urethra—vulva cancer	0.00956	0.00956	CbGeAlD
Nilotinib—EPHB6—uterine cervix—vulva cancer	0.00952	0.00952	CbGeAlD
Nilotinib—EPHA2—urethra—vulva cancer	0.00938	0.00938	CbGeAlD
Nilotinib—TEK—urethra—vulva cancer	0.00915	0.00915	CbGeAlD
Nilotinib—EPHB4—mammalian vulva—vulva cancer	0.0091	0.0091	CbGeAlD
Nilotinib—EPHA2—mammalian vulva—vulva cancer	0.00893	0.00893	CbGeAlD
Nilotinib—HCK—vagina—vulva cancer	0.00887	0.00887	CbGeAlD
Nilotinib—ABL2—vagina—vulva cancer	0.00882	0.00882	CbGeAlD
Nilotinib—EPHB6—urethra—vulva cancer	0.00874	0.00874	CbGeAlD
Nilotinib—MAPK11—lymph node—vulva cancer	0.00844	0.00844	CbGeAlD
Nilotinib—CDC42BPB—lymph node—vulva cancer	0.00838	0.00838	CbGeAlD
Nilotinib—EPHB6—mammalian vulva—vulva cancer	0.00833	0.00833	CbGeAlD
Nilotinib—MAP2K5—uterine cervix—vulva cancer	0.00814	0.00814	CbGeAlD
Nilotinib—EPHA4—vagina—vulva cancer	0.00807	0.00807	CbGeAlD
Nilotinib—CA3—vagina—vulva cancer	0.00797	0.00797	CbGeAlD
Nilotinib—CSF1R—uterine cervix—vulva cancer	0.00794	0.00794	CbGeAlD
Nilotinib—EPHA3—lymph node—vulva cancer	0.00794	0.00794	CbGeAlD
Nilotinib—MAPK8—lymph node—vulva cancer	0.00757	0.00757	CbGeAlD
Nilotinib—MAP2K5—urethra—vulva cancer	0.00748	0.00748	CbGeAlD
Nilotinib—MAPK14—vagina—vulva cancer	0.00744	0.00744	CbGeAlD
Nilotinib—FGR—vagina—vulva cancer	0.00741	0.00741	CbGeAlD
Nilotinib—LCK—vagina—vulva cancer	0.00741	0.00741	CbGeAlD
Nilotinib—CSF1R—urethra—vulva cancer	0.0073	0.0073	CbGeAlD
Nilotinib—KIT—epithelium—vulva cancer	0.00727	0.00727	CbGeAlD
Nilotinib—KIT—uterine cervix—vulva cancer	0.00721	0.00721	CbGeAlD
Nilotinib—MAP2K5—mammalian vulva—vulva cancer	0.00712	0.00712	CbGeAlD
Nilotinib—PDGFRB—epithelium—vulva cancer	0.0071	0.0071	CbGeAlD
Nilotinib—EPHB4—vagina—vulva cancer	0.00705	0.00705	CbGeAlD
Nilotinib—PDGFRB—uterine cervix—vulva cancer	0.00704	0.00704	CbGeAlD
Nilotinib—CSF1R—mammalian vulva—vulva cancer	0.00695	0.00695	CbGeAlD
Nilotinib—EPHA2—vagina—vulva cancer	0.00692	0.00692	CbGeAlD
Nilotinib—MAP4K1—lymph node—vulva cancer	0.00688	0.00688	CbGeAlD
Nilotinib—KIT—urethra—vulva cancer	0.00663	0.00663	CbGeAlD
Nilotinib—TIE1—lymph node—vulva cancer	0.00657	0.00657	CbGeAlD
Nilotinib—PDGFRB—urethra—vulva cancer	0.00647	0.00647	CbGeAlD
Nilotinib—EPHB6—vagina—vulva cancer	0.00645	0.00645	CbGeAlD
Nilotinib—KIT—mammalian vulva—vulva cancer	0.00631	0.00631	CbGeAlD
Nilotinib—BRAF—lymph node—vulva cancer	0.0063	0.0063	CbGeAlD
Nilotinib—ABL1—uterine cervix—vulva cancer	0.00628	0.00628	CbGeAlD
Nilotinib—EPHB3—lymph node—vulva cancer	0.00625	0.00625	CbGeAlD
Nilotinib—PDGFRB—mammalian vulva—vulva cancer	0.00616	0.00616	CbGeAlD
Nilotinib—PDGFRA—vagina—vulva cancer	0.00611	0.00611	CbGeAlD
Nilotinib—ABL1—urethra—vulva cancer	0.00577	0.00577	CbGeAlD
Nilotinib—HCK—lymph node—vulva cancer	0.00574	0.00574	CbGeAlD
Nilotinib—ABL2—lymph node—vulva cancer	0.0057	0.0057	CbGeAlD
Nilotinib—MAP2K5—vagina—vulva cancer	0.00551	0.00551	CbGeAlD
Nilotinib—ABL1—mammalian vulva—vulva cancer	0.00549	0.00549	CbGeAlD
Nilotinib—CSF1R—vagina—vulva cancer	0.00538	0.00538	CbGeAlD
Nilotinib—EPHA4—lymph node—vulva cancer	0.00522	0.00522	CbGeAlD
Nilotinib—CA3—lymph node—vulva cancer	0.00515	0.00515	CbGeAlD
Nilotinib—KIT—vagina—vulva cancer	0.00489	0.00489	CbGeAlD
Nilotinib—MAPK14—lymph node—vulva cancer	0.00481	0.00481	CbGeAlD
Nilotinib—FGR—lymph node—vulva cancer	0.00479	0.00479	CbGeAlD
Nilotinib—LCK—lymph node—vulva cancer	0.00479	0.00479	CbGeAlD
Nilotinib—PDGFRB—vagina—vulva cancer	0.00477	0.00477	CbGeAlD
Nilotinib—CA4—urethra—vulva cancer	0.00474	0.00474	CbGeAlD
Nilotinib—EPHB4—lymph node—vulva cancer	0.00456	0.00456	CbGeAlD
Nilotinib—EPHA2—lymph node—vulva cancer	0.00447	0.00447	CbGeAlD
Nilotinib—TEK—lymph node—vulva cancer	0.00436	0.00436	CbGeAlD
Nilotinib—CA2—epithelium—vulva cancer	0.00431	0.00431	CbGeAlD
Nilotinib—ABL1—vagina—vulva cancer	0.00425	0.00425	CbGeAlD
Nilotinib—EPHB6—lymph node—vulva cancer	0.00417	0.00417	CbGeAlD
Nilotinib—ABCG2—uterine cervix—vulva cancer	0.00396	0.00396	CbGeAlD
Nilotinib—PDGFRA—lymph node—vulva cancer	0.00395	0.00395	CbGeAlD
Nilotinib—CA2—mammalian vulva—vulva cancer	0.00374	0.00374	CbGeAlD
Nilotinib—ABCG2—urethra—vulva cancer	0.00364	0.00364	CbGeAlD
Nilotinib—MAP2K5—lymph node—vulva cancer	0.00357	0.00357	CbGeAlD
Nilotinib—CSF1R—lymph node—vulva cancer	0.00348	0.00348	CbGeAlD
Nilotinib—ABCG2—mammalian vulva—vulva cancer	0.00346	0.00346	CbGeAlD
Nilotinib—KIT—lymph node—vulva cancer	0.00316	0.00316	CbGeAlD
Nilotinib—PDGFRB—lymph node—vulva cancer	0.00309	0.00309	CbGeAlD
Nilotinib—CA2—vagina—vulva cancer	0.0029	0.0029	CbGeAlD
Nilotinib—CA1—lymph node—vulva cancer	0.00289	0.00289	CbGeAlD
Nilotinib—CYP2C8—vagina—vulva cancer	0.00276	0.00276	CbGeAlD
Nilotinib—ABL1—lymph node—vulva cancer	0.00275	0.00275	CbGeAlD
Nilotinib—ABCG2—vagina—vulva cancer	0.00268	0.00268	CbGeAlD
Nilotinib—CYP2B6—vagina—vulva cancer	0.00247	0.00247	CbGeAlD
Nilotinib—CA4—lymph node—vulva cancer	0.00226	0.00226	CbGeAlD
Nilotinib—ABCB1—epithelium—vulva cancer	0.00197	0.00197	CbGeAlD
Nilotinib—ABCB1—uterine cervix—vulva cancer	0.00195	0.00195	CbGeAlD
Nilotinib—CA2—lymph node—vulva cancer	0.00187	0.00187	CbGeAlD
Nilotinib—ABCB1—urethra—vulva cancer	0.00179	0.00179	CbGeAlD
Nilotinib—ABCG2—lymph node—vulva cancer	0.00174	0.00174	CbGeAlD
Nilotinib—ABCB1—mammalian vulva—vulva cancer	0.00171	0.00171	CbGeAlD
Nilotinib—ABCB1—vagina—vulva cancer	0.00132	0.00132	CbGeAlD
Nilotinib—ABCB1—lymph node—vulva cancer	0.000856	0.000856	CbGeAlD
